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Oestrogen and progesterone have been shown to have impact on cystic fibrosis transmembrane conductance
regulator (CFTR) gene expression, tone of smooth muscle in the airways, immune response, exhaled nitric oxide
and cytology in the tracheobronchial epithelium. The aim of this investigation was to study the influence of
menstrual cyclicity on airway symptoms among cystic fibrosis (CF) females.
Twelve CF women (mean age 30 years, mean Shwachman score 85) kept daily records during three menstrual
cycles of lung function, sputum quality and need for intravenous antibiotics. Paired t-test was used as a statistical
method to compare the airway symptoms between the time of ovulation (high levels of oestrogen and low levels of
progesterone), the luteal phase (high levels of oestrogen and progesterone) and menstruation (low levels of
oestrogens and progesterone).
Forced expiratory volume in 1 sec (FEV1) was significantly higher during the luteal phase (66% of predicted)
compared to during ovulation (63%) and menstruation (61%) (P50?01). Forced vital capacity (FVC) showed the
same pattern, being significantly higher during the luteal phase compared with during menstruation (mean 75% vs.
70%, P50?01).
In conclusion, lung function changes were found during menstrual cycles in women with cystic fibrosis. These
changes are probably related to changes in progesterone levels during the menstrual cycles. This result warrants
further studies to understand the complexity of CF lung disease in women.
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Cystic fibrosis (CF) is the most common autosomal
recessive lethal disease among the Caucasian population.
It is caused by mutations of the gene encoding for cystic
fibrosis transmembrane conductance regulator (CFTR).
CFTR is a cAMP-regulated chloride channel, ATP-
transporter and a regulator of sodium channels. CF is
characterized by abnormal thick mucus with symptoms
mainly from the respiratory and gastrointestinal tract (1).
Previous studies have shown that sexual hormones have
impact on CFTR mRNA expression, (2,3), the tone of
smooth muscle in the airways (4), airway responsiveness (5)
the immune response (6) and exhaled nitric oxide (NO) (7).
The tracheobronchial epithelium also shows cytological
changes during the menstrual cycle (8).
In our experience it is not unusual that female patients
with CF have reported worsening of lung symptoms priorReceived 24 November 1999 and accepted in revised form 18 May
2000. Published online 12 September 2000.
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0954-6111/00/111043+04 $35?00/0to menstruation. Therefore, we wanted to study whether
the menstrual cyclicity of sexual hormones influences lung
function and airway symptoms among these patients.
Methods
Twelve CF women with regular menstruation, now using
oral contraceptives, kept daily records during three
menstrual cycles on lung function, sputum quality and
need for intravenous antibiotics.
Clinical status was evaluated by Schwachman score (9)
and pulmonary function by micro-spirometer (Micro
Medical Ltd, Chatham, Kent, U.K.) in the morning before
inhalation of bronchodilators and chest physiotherapy.
Forced vital capacity (FVC) and forced expiratory volume
in 1 sec (FEV1) were compared with appropriate reference
values and expressed as percentage of the reference values
(10). The patients were asked to subjectively score the
degree of tenacity of sputum on a scale from one to four.
Intravenous antibiotic treatments were started when the
patients presented one or several signs of low-grade
infection (11).
Three time periods during menstruation were chosen
from the daily records for comparison. (1) Ovulation, 24 h# 2000 HARCOURT PUBLISHERS LTD
FIG. 1. Forced expiratory volume in 1 sec (FEV1) during
the menstrual cycle (individual changes and
mean,**=P50?01).
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oestrogen and low levels of progesterone (12). For
determination of LH peak, morning urine samples were
collected from cycle days 10–15, using a self-test (Ovu
Qvick: Monoclonal Antibiotics Inc. Sunnyvale, CA,
U.S.A.). (2) The luteal phase, 6–8 days prior to menstrua-
tion, characterized by high progesterone and oestrogen
levels. (3) Second to fourth day of menstruation with low
levels of oestrogen and progesterone (12).
STATISTICS
Mean values for the three menstrual cycles were used in the
analysis. Comparisons between mean FEV1 and FVC
during the three different time periods were made using
ANOVA (repeated measurements) and paired t-test. FEV1
and FVC was log-transformed in order to achieve a normal
distribution. Comparisons between use of antibiotics and
sputum quality between the three time periods were made
with the Kruskal–Wallis test. The intra-individual correla-
tion coecient was calculated when comparing FEV1 and
FVC from the three menstrual cycles within in each subject.
A P-value 5 0?05 was considered significant. The results
are presented as mean+SD.
Results
Patient characteristics are presented in Table 1. All but one
of the patient were colonized with Pseudomonas aeruginosa.
FEV1 was significantly higher during the luteal phase
66+20% compared to during ovulation 63+20% and
menstruation 61+20 (P50?01; Fig. 1). FVC showed the
same pattern, being significantly higher during the luteal
phase compared to during menstruation (75+17% vs.
70+17, P50?01; Fig. 2). Mean FVC during ovulation was
lower (72+18%) than during the luteal phase, but this
difference was not statistically significant (P=0?051). TheTABLE 1. Patient characteristics
Patient Genotype* Age Age at diagnosis S
1 þ/7 39 18
2 þ/þ 31 At birth
3 þ/þ 30 2
4 þ/7 39 34
5 þ/þ 33 4
6 þ/7 31 2
7 þ/þ 30 At birth
8 þ/7 27 4
9 þ/þ 24 At birth
10 þ/þ 23 At birth
11 þ/7 32 1
12 þ/7 18 4
*þ/þhomozygous for delta F508, þ/7heterozygous for delta F
{One week prior to menstruation.total number of courses of intravenous antibiotics was 28
during the 3-months study period. Nine of the courses were
started during ovulation, eight during the luteal phase and
11 during menstruation (non-significant). No statistical
difference in sputum quality was found when comparing the
three time periods.
There were no significant differences in mean FEV1 and
FVC in the three menstrual cycles. The intra-individual
correlation in FEV1 and FVC in the three cycles varied
between 0?95 and 0?99.hwachman score FEV1
{ (% pred) FVC{ (% pred)
80 59 72
75 46 57
75 46 55
90 92 93
80 37 59
95 95 99
90 90 93
80 47 51
85 78 86
80 68 81
85 77 91
90 59 61
508.
FIG. 2. Forced vital capacity (FVC) during the menstrual
cycle (individual changes and mean,**=P50?01).
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In our study we found lung function changes during
menstrual cycles in women with cystic fibrosis. This is in
contrast to a previous, less extensive, study (13). This
discrepancy might be related to the fact that we studied
different time periods during the menstrual cycle and
thereby different levels of sexual hormones (12).
Cystic fibrosis and asthma share common features such
as bronchial responsiveness (14) and increased eosinophilic
activation (15). There are reports of increased frequency of
exacerbation of asthma during menstruation when proges-
terone and oestrogen levels are low (16). Increased
bronchial responsiveness and decreased peak flow have
also been found in women with asthma during the
menstrual phase (5,17). The mechanism behind these
menstrual cycle related changes are not known but previous
studies have shown that progesterone may relax the tone of
the smooth muscle in the airways (4). Leukotrienes seem to
be partly involved in the pathogenesis of premenstrual
exacerbations of asthma and leukotriene antagonists may
prevent airflow obstruction in these patients (18). Changes
in airway concentration of nitric oxide during the menstrual
cycle with the lowest NO levels during menstruation have
been observed (7). Although NO is a mediator of
bronchodilation the physiological significance of this finding
is still not known and inhaled NO at physiological levels
present in the airways of normal individuals does not seem
to change lung function in patients with cystic fibrosis (19).
The mean change in FEV1 and FVC between the luteal
phase and menstruation was 153ml and 173ml, respec-
tively. This magnitude of change was relatively low andprobably not clinically detectable in most patients. Only
one patient had a mean decrease in FEV1 above 10% of
predicted during ovulation and menstruation compared to
the luteal phase. The changes in FEV1 and FVC were,
however, consistent with higher lung function level during
the luteal in nearly all patients. The luteal phase is
characterized by high levels of both progesterone and
oestrogen compared to ovulation when progesterone levels
are low but oestrogen is high, and during menstruation
when the levels of both sex hormones are low (12). This
indicates that the changes in lung function in the present
study were related to changes in progesterone levels. Our
data is in accordance with the data on asthma exacerba-
tions in women, where the lowest prevalence of exacerba-
tions was found in the luteal phase (16).
We were unable to detect any statistical differences in
sputum quality using a subjective scoring system or in the
use of intravenous antibiotics during the menstrual cycle.
In conclusion lung function changes were found during
menstrual cycles in women with cystic fibrosis. It is
probably related to changes in progesterone levels during
the menstrual cycles. This results warrants further studies to
understand the complexity of CF lung disease in women.
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